Vaccine Miracles: Does JNJ Kill the Profit Path for MRNA and NVAX?

Investor Tips
New vaccine entrant gets approval before Novavax, while herd immunity ideas put sales in doubt.

Articles You May Like

Mortgage demand sinks even as rates drop
Stock futures are little changed following third straight day of gains for S&P 500
Self-made millionaire and finance expert shares her top 18 ‘recession money rules’: It’s ‘reasonable to be worried’
Op-ed: This ‘unfamiliar’ type of bond fund may offer opportunities for fixed-income investors
I made a mistake on my return. What do I do?